Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORMAT Study
2024-516494-73-00Phase 2Completed
- Sponsor
- CHU Saint-Etienne
- Start
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Fibrinogen human in hematopoietic malignancies, Thrombocytopenia and Bleeding, sponsored by CHU Saint-Etienne. Primary endpoint: Change in maximum clot elasticity (MCE) on EXTEM ROTEM between pre- and post-treatment. Started Aug 2024; status: completed.
02
Drugs
Fibrinogen human
03
Conditions
hematopoietic malignanciesThrombocytopeniaBleeding
Beyond the preview
Go deeper on 2024-516494-73-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516494-73-00.